Novartis | NVS - Interest Expense On Debt


Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bausch Health Companies USD 412M 53M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
J&J USD 18M 290M Sep/2025
Merck USD 412M 85M Dec/2025
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Phibro Animal Health USD 8.76M 2.76M Sep/2024
Prestige Brands USD 10.67M 636K Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sanofi EUR -25M 99.78M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 57M 1000K Dec/2025